Brian R. Adams J.D.
Net Worth
Last updated:
What is Brian R. Adams J.D. net worth?
The estimated net worth of Mr. Brian R. Adams J.D. is at least $4,707,174 as of 27 Jun 2024. He owns shares worth $1,106,605 as insider, has earned $760,319 from insider trading and has received compensation worth at least $2,840,250 in Relay Therapeutics, Inc..
What is the salary of Brian R. Adams J.D.?
Mr. Brian R. Adams J.D. salary is $568,050 per year as Gen. Counsel & Sec. in Relay Therapeutics, Inc..
How old is Brian R. Adams J.D.?
Mr. Brian R. Adams J.D. is 51 years old, born in 1974.
What stocks does Brian R. Adams J.D. currently own?
As insider, Mr. Brian R. Adams J.D. owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Relay Therapeutics, Inc. (RLAY) | Gen. Counsel & Sec. | 325,472 | $3.4 | $1,106,605 |
What does Relay Therapeutics, Inc. do?
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Brian R. Adams J.D. insider trading
Relay Therapeutics, Inc.
Mr. Brian R. Adams J.D. has made 29 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 295 units of RLAY stock worth $1,847 on 27 Jun 2024.
The largest trade he's ever made was exercising 10,000 units of RLAY stock on 20 Jul 2020. As of 27 Jun 2024 he still owns at least 325,472 units of RLAY stock.
Relay Therapeutics key executives
Relay Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Donald A. Bergstrom M.D., Ph.D. (53) Executive Vice President and Head of R&D
- Dr. Mark Murcko Ph.D. (65) Co-Founder & Director
- Dr. Sanjiv K. Patel MBBS, M.A., M.D., M.B.A. (51) Chief Executive Officer, Pres & Director
- Mr. Alexis A. Borisy A.M. (53) Co-Founder & Independent Chairman
- Mr. Brian R. Adams J.D. (51) Gen. Counsel & Sec.